Lyra Therapeutics (LYRA) Cash from Restructuring (2024 - 2025)
Lyra Therapeutics (LYRA) posted Cash from Restructuring of $207000.0 for Q4 2025, up 148.48% on a QoQ basis from -$427000.0 in Q3 2025, and up 140.75% year-over-year from $85982.0 in Q4 2024.
Powered by 
Analysis
Lyra Therapeutics (LYRA) Cash from Restructuring (2024 - 2025) Analysis & Trends
Lyra Therapeutics has reported Cash from Restructuring for 2 years, with the latest figure at $207000.0 in Q4 2025.
- On a quarterly basis, Cash from Restructuring rose 140.75% year-over-year to $207000.0 in Q4 2025; TTM through Dec 2025 was -$1.1 million, a N/A change from a year earlier, with the FY2025 full-year figure at -$1.1 million, down 124.87% from the prior year.
- Cash from Restructuring was $207000.0 for Q4 2025 at Lyra Therapeutics, up from -$427000.0 in the prior quarter.
- The five-year high for Cash from Restructuring was $1.7 million in Q3 2024, with the low at -$553000.0 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Lyra Therapeutics | 354,976.41 | 354,976.41 | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 207,000.00 |
| Sep 30, 2025 | -427,000.00 |
| Jun 30, 2025 | -553,000.00 |
| Mar 31, 2025 | -308,000.00 |
| Dec 31, 2024 | -508,000.00 |
| Sep 30, 2024 | 1.73 Mn |